Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Candel Therapeutics, Inc. (CADL) AI Forecast

Our AI analyzed Candel Therapeutics, Inc.. Create a free account and follow it to see the 90-day price prediction.

Free account • 30-day free trial

$CADL Neutral Signal Full forecast available

Candel Therapeutics, Inc. (CADL) Stock Forecast 2025


Candel Therapeutics, Inc. (CADL) AI Stock Price Forecast & Investment Analysis

Candel Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Candel Therapeutics, Inc. (CADL) - Comprehensive Stock Analysis & Investment Research

Deep dive into Candel Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 3:42 p.m. (UTC)

Candel Therapeutics, Inc. Investment Summary

When evaluating whether Candel Therapeutics, Inc. (CADL) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Candel Therapeutics, Inc. (CADL) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $722 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Candel Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Candel Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Candel Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Candel Therapeutics, Inc.

Sign Up Free
Corporate Identity

Candel Therapeutics, Inc. (Stock Symbol: CADL) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Candel Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Candel Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Candel Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Candel Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Candel Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Candel Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Candel Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Candel Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Candel Therapeutics, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Candel Therapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Candel Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-49 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 28.05 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Candel Therapeutics, Inc. (CADL) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Candel Therapeutics, Inc. stock analysis.

Deep dive into Candel Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Candel Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Candel Therapeutics, Inc.:

P/B Ratio 5.23x
Market Cap $722M
Book Value/Share $1.88
FCF/Share $-0.67
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Candel Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Candel Therapeutics, Inc.: An ROE of -62.5% indicates room for improvement in shareholder value creation.

ROE -62.5%
ROA -42.7%
ROIC -20.4%
Operating Margin -15804.8%
Net Margin -34219.1%
EBT Margin -15804.8%
Tax Rate -0.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Candel Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Candel Therapeutics, Inc.: A current ratio of 28.05 indicates strong liquidity.

Current Ratio 28.05x
D/E Ratio 0.46x
Financial Leverage 1.46x
Interest Coverage -10.4x
Working Capital $191M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Candel Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Candel Therapeutics, Inc.: Free cash flow of $-49M indicates cash challenges that need attention.

Operating Cash Flow -$40M
Free Cash Flow -$49M
Capital Spending -$9M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Candel Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Candel Therapeutics, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Candel Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Candel Therapeutics, Inc.:

Income Statement
Operating Income -$39M
Net Income -$86M
R&D Expense $24M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 198%
Cash & Short-term Investments 195%
Total Liabilities 64%
Short-term Debt 4%
Dividend & Shareholder Information
Shares Outstanding 73M
Growth Metrics (YoY)
Net Income Growth -34219.1%

Latest Candel Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Candel Therapeutics, Inc. (CADL) stock price and investment outlook.

📰 Loading...

Candel Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Candel Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $157M x 1.8x
ABPO ██% $1M x x
ACOG ██% $179M x 3.1x
ADAPY ██% $8M x x
ADMA ██% $1.94B 11.8x 5.0x
ADPT ██% $3.56B x 16.5x
AGEN ██% $238M 3.7x x
AGTX ██% $800K x x
AIM ██% $7M x 3.3x
ALEC ██% $165M x 15.9x
ALGS ██% $29M x 0.9x
ALLO ██% $628M x 2.3x
ALVO ██% $992M x x
AMGN ██% $200.50B 25.7x 21.8x
APGE ██% $10.05B x x
APTOF ██% $4M x x
ARGX ██% $57.22B x x
ARMP ██% $192M x x
ARTV ██% $492M x 5.6x
ATRA ██% $70M x x
ATYR ██% $49M x 0.8x
AURA ██% $745M x 6.9x
AUTL ██% $405M x 3.7x
AVXL ██% $230M x 1.8x
BCAB ██% $6M x x
BCDA ██% $14M x x
BCLI ██% $11M x x
BCRX ██% $2.38B x x
BDTX ██% $105M x 1.0x
BEAM ██% $2.66B x 2.3x
BIIB ██% $29.53B 21.5x 1.6x
BNTX ██% $23.28B x x
CABA ██% $444M x 4.3x
CADL ██% $722M x 5.2x
CCCC ██% $380M x 1.6x
CELZ ██% $5M x 0.9x
CERO ██% $500K x x
CGEM ██% $1.06B x 2.9x
CGEN ██% $221M 3.1x 2.2x
CGON ██% $6.26B x 5.7x
CGTX ██% $86M x 2.9x
CHRS ██% $221M 1.2x 2.8x
CLDI ██% $2M x 0.4x
CLLS ██% $279M x x
CMPX ██% $382M x 2.1x
CPMV ██% $5M x x
CRDF ██% $65M x 1.9x
CRDL ██% $123M x x
CRIS ██% $9M x 0.7x
CRSP ██% $4.58B x 2.5x
CSBR ██% $83M x 19.5x
CVM ██% $21M x 3.0x
DBVT ██% $820M x 5.1x
DNA ██% $489M x 1.1x
DNLI ██% $3.72B x 4.0x
DTIL ██% $189M x 2.5x
DYAI ██% $44M x x
EDIT ██% $419M x 95.0x
ELUT ██% $40M 0.8x 1.8x
ENGN ██% $127M x 0.5x
ENTX ██% $99M x 9.3x
ENZN ██% $59M x 0.3x
ESLA ██% $32M x x
EVAX ██% $25M x x
EXEL ██% $14.12B 16.9x 7.3x
EXOZ ██% $40M x 26.1x
FATE ██% $293M x 1.6x
FDMT ██% $543M x 1.2x
FENC ██% $351M x 9.3x
GILD ██% $162.53B 17.6x 6.9x
GLUE ██% $1.94B x 3.7x
GNTA ██% $80M x 6.4x
GPLB ██% $260K x x
GRML ██% $30M x 0.6x
HALO ██% $9.58B 27.5x 43.6x
HUMA ██% $172M x 14.8x
IBRX ██% $7.75B x x
IKT ██% $366M x 2.2x
IMA ██% $63M x 0.5x
IMCR ██% $1.81B x 4.6x
IMTX ██% $1.25B x x
IMVT ██% $8.03B x 9.4x
INAB ██% $12M x 0.5x
INKT ██% $50M x x
INMB ██% $46M x 2.3x
INTS ██% $11M x 1.1x
IOVA ██% $2.25B x 3.1x
IPSC ██% $391M x 1.5x
IVVD ██% $172M x 0.9x
JATT ██% $88M x 0.4x
JSPR ██% $24M x 7.1x
KLRS ██% $90M x 1.3x
KOD ██% $2.55B x 22.7x
KRYS ██% $9.64B 42.8x 7.6x
KYMR ██% $9.07B x 5.9x
KYTX ██% $441M x 2.3x
LCTX ██% $267M x 5.0x
LENZ ██% $158M x 0.6x
LIFE ██% $1.87B x 32.2x
LIMN ██% $7M x x
LONA ██% $68M x 1.4x
LXEO ██% $349M x 1.5x
MAZE ██% $1.53B x 4.5x
MESO ██% $2.09B x x
MGTX ██% $986M x x
MGX ██% $46M x 0.3x
MOLN ██% $160M x x
MRNA ██% $22.64B x 3.1x
NBIX ██% $17.52B 26.2x 5.1x
NMRA ██% $281M x 4.0x
NVAX ██% $1.29B x x
OCGN ██% $430M x 74.0x
OTLK ██% $247M x x
PALI ██% $338M x 2.7x
PASG ██% $16M x 1.3x
PCVX ██% $8.03B x 2.7x
PHGE ██% $2M x x
PLUR ██% $19M x x
PLX ██% $189M 12.3x 2.8x
PMCB ██% $6M x 0.2x
PRME ██% $536M x 7.0x
PROK ██% $459M x x
PTHS ██% $96M x 2.7x
QGEN ██% $8.99B x 2.4x
QNCX ██% $18M 2.1x 1.1x
REPL ██% $865M x 5.2x
RGEN ██% $7.76B 151.0x 3.7x
RGNX ██% $656M x 31.1x
RLAY ██% $4.14B x 6.5x
RVMD ██% $37.78B x 25.2x
RXRX ██% $1.60B x 1.6x
SABS ██% $274M x 1.2x
SANA ██% $866M x 7.3x
SCLX ██% $52M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $25M x x
SLDB ██% $804M x 2.2x
SLXN ██% $3M x 8.7x
SNTI ██% $13M x 5.2x
SRRK ██% $5.89B x 21.4x
SRZN ██% $231M x x
STRO ██% $391M x x
TARA ██% $226M x 1.3x
TARS ██% $2.52B x 7.2x
TCRX ██% $52M x 0.5x
TECH ██% $11.23B 102.5x 5.4x
TECX ██% $594M x 2.6x
TIL ██% $48M x 0.4x
TNYA ██% $168M x 1.6x
TSHA ██% $1.67B x 7.9x
TVGN ██% $20M x x
TWST ██% $5.75B x 12.6x
VACH ██% $541M 80.4x x
VALN ██% $516M x x
VCEL ██% $2.30B 107.1x 6.5x
VIR ██% $1.51B x 1.9x
VIVS ██% $2M x 0.4x
VOR ██% $1.03B x x
VXRT ██% $121M 3.3x 1.3x
VYGR ██% $185M x 1.1x
WINT ██% $340K x x
XFOR ██% $376M x 2.2x
ZEOX ██% $14M x 19.4x
ZIVO ██% $19M x x
ZURA ██% $502M x 2.3x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Candel Therapeutics, Inc. Stock Forecast

How accurate are Candel Therapeutics, Inc. stock predictions?

Our AI model shows a 53% Spearman correlation coefficient for CADL predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Candel Therapeutics, Inc. stock price forecasts?

Our analysis considers Candel Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Candel Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Candel Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Candel Therapeutics, Inc. forecasts updated?

Candel Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Candel Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...